整理 | GLP1减重宝典内容团队 3月4日世界肥胖日把一个长期被低估的公共议题推到台前。多份公开材料显示，肥胖已不再只是生活方式问题，而是与糖尿病、心血管等慢病 高度耦合、需要长期干预的复发性疾病；企业端也开始用"生产率损失"和"健康成本"来重新计量它。第一财经报道援引礼来中国的测算称， 2025年我国超重与肥胖相关的总经济成本已达约1万亿元人民币。 在"体重管理年行动"提出一年后，体重管理在2026年全国两会继续升温，讨论焦点也从喊口号转向补体系、补支付、补院外服务。全国人大代 表、迈普医学董事长袁玉宇表示，将把建议重点放在慢病与体重管理的院外连续服务体系建设，以及优化糖尿病等慢病的社会保障安排上。 围绕"院外怎么管"，来自临床与产业调研的一线声音把痛点讲得更直白：药物疗效上来了，但停药后反弹与长期随访缺位，让不少人陷入反复 治疗的循环。南方+报道的专题座谈中，南京鼓楼医院内分泌专家毕艳提到，体重管理存在重倡导轻服务、重院内轻院外等结构性矛盾；多位专 家同时将关键瓶颈指向支付与收费机制——院外管理缺少可复制的服务包、可对接的医保或商保支付路径，导致"有人愿意做、体系难以持 续"。 该座谈中，安徽医科大学校 ...

Core Insights - The article highlights the discovery of a large quantity of illegal weight loss drugs containing methamphetamine, a controlled substance, by customs officials in Hefei [2][4]. Group 1: Regulatory Issues - Methamphetamine is classified as a first-class psychoactive drug in China, known for its addictive properties and is the active ingredient in ice drugs [4]. - According to the Drug Administration Law of the People's Republic of China, the import and export of narcotic drugs and certain psychoactive substances require permits issued by the State Drug Administration [4]. Group 2: Industry Context - The article emphasizes the growing concern over the illegal trade of weight loss drugs, particularly those containing harmful substances, which poses risks to public health [2][4]. - The GLP-1 drug class is mentioned as a new category of weight loss and diabetes management medications, which work by enhancing insulin secretion and suppressing appetite [11].